ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,146.86
-0.21%
Dow Jones
38,589.16
-0.15%
Gold vs US Dollar
2,333.015
0.00%
Brent Oil
82.275
0.00%
Bitcoin
66,666.69
0.72%
Pepperstone
Advertisement
Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NYSE
  6. Johnson and Johnson (JNJ)

  7. Johnson and Johnson (JNJ) News

Johnson and Johnson (JNJ)

Johnson and Johnson
Date:
Sort by:
 Showing the most relevant articles for your search:NYSE:JNJ
DateTimeSourceHeadlineSymbolCompany
15/06/202408:30PR Newswire (US)Late-breaking results show nipocalimab significantly improves Sjögren's disease activity in a Phase 2 studyNYSE:JNJJohnson and Johnson
14/06/202413:00PR Newswire (US)TALVEY® (talquetamab-tgvs) demonstrates highly durable, longer-term responses in patients with relapsed or refractory multiple myelomaNYSE:JNJJohnson and Johnson
12/06/202419:26Business WireTalc Plaintiffs File Motion for Temporary Restraining Order to Limit Johnson & Johnson’s Use of Bankruptcy StrategyNYSE:JNJJohnson and Johnson
12/06/202412:19IH Market NewsParamount Ends Skydance Talks, Oracle Shares Surge 8.7% on New Partnerships, and More NewsNYSE:JNJJohnson and Johnson
06/06/202422:07Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:JNJJohnson and Johnson
06/06/202422:07Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:JNJJohnson and Johnson
05/06/202412:41IH Market NewsApollo Buys 49% of Intel’s Irish Plant for $11bn, BlackRock and Citadel to Create Texas Exchange, and More NewsNYSE:JNJJohnson and Johnson
04/06/202421:30Business WireJohnson & Johnson to Host Investor Conference Call on Second-Quarter ResultsNYSE:JNJJohnson and Johnson
31/05/202413:45Business WireJohnson & Johnson Completes Acquisition of Shockwave MedicalNYSE:JNJJohnson and Johnson
29/05/202422:48PR Newswire (US)Sarepta Therapeutics Set to Join S&P MidCap 400NYSE:JNJJohnson and Johnson
28/05/202421:10Edgar (US Regulatory)Form SD - Specialized disclosure reportNYSE:JNJJohnson and Johnson
28/05/202412:35GlobeNewswire Inc.Numab Therapeutics Announces Johnson & Johnson to Acquire its Wholly-Owned Subsidiary Yellow Jersey Therapeutics Including Rights to NM26, a Bi-Specific Antibody for the Treatment of Atopic DermatitisNYSE:JNJJohnson and Johnson
28/05/202412:30Business WireJohnson & Johnson to Obtain Rights to a Clinical-Stage Bispecific Antibody to Address Distinct Patient Needs in Atopic DermatitisNYSE:JNJJohnson and Johnson
22/05/202417:05Business WireProposed Class Action Filed by Six Law Firms Alleging Series of Fraudulent Transfers by Johnson & Johnson in Talc LitigationNYSE:JNJJohnson and Johnson
21/05/202415:43Edgar (US Regulatory)Form CERT - Certification by an exchange approving securities for listingNYSE:JNJJohnson and Johnson
20/05/202422:17Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NYSE:JNJJohnson and Johnson
20/05/202421:34Edgar (US Regulatory)Form 8-A12B - Registration of securities [Section 12(b)]NYSE:JNJJohnson and Johnson
20/05/202421:01Edgar (US Regulatory)Form 8-K - Current reportNYSE:JNJJohnson and Johnson
20/05/202414:31Edgar (US Regulatory)Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securitiesNYSE:JNJJohnson and Johnson
17/05/202416:21Edgar (US Regulatory)Form 8-K - Current reportNYSE:JNJJohnson and Johnson
17/05/202412:36IH Market NewsOpenAI’s Reddit Partnership Boosts Shares by 14%, Microsoft Embraces AMD Chips for AI, and More NewsNYSE:JNJJohnson and Johnson
16/05/202421:16Edgar (US Regulatory)Form 424B2 - Prospectus [Rule 424(b)(2)]NYSE:JNJJohnson and Johnson
16/05/202412:30Business WireJohnson & Johnson to Acquire Proteologix, Inc. to Lead in Atopic Dermatitis TreatmentNYSE:JNJJohnson and Johnson
14/05/202422:01Edgar (US Regulatory)Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectusesNYSE:JNJJohnson and Johnson
14/05/202412:26IH Market NewsWalmart Corporate Job Cuts and Office Centralization, GameStop and AMC Surge, and More NewsNYSE:JNJJohnson and Johnson
14/05/202411:05Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NYSE:JNJJohnson and Johnson
13/05/202413:36Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NYSE:JNJJohnson and Johnson
10/05/202422:14Edgar (US Regulatory)Form 13F-HR - Quarterly report filed by institutional managers, HoldingsNYSE:JNJJohnson and Johnson
08/05/202421:30Business WireJohnson & Johnson to Participate in the Goldman Sachs 45th Annual Global Healthcare ConferenceNYSE:JNJJohnson and Johnson
06/05/202421:05GlobeNewswire Inc.Shockwave Medical Reports First Quarter 2024 Financial ResultsNYSE:JNJJohnson and Johnson
 Showing the most relevant articles for your search:NYSE:JNJ

Your Recent History

LSE
LLOY
Lloyds Banking
LSE
PANR
Pantheon Resources
LSE
GOLD
LSE
BIRD
Blackbird
LSE
VAST
Vast Resources
LSE
NEXN
Nexxen
LSE
ARCM
Arc Minerals
LSE
NSCI
Netscientific
LSE
ENET
Ethernity Networks
LSE
GNC
Greencore
LSE
LGEN
Legal & General
LSE
SBTX
Skinbiotherapeutics
LSE
PHNX
Phoenix
LSE
HE1
Helium One Global
LSE
GMET
Golden Metal Resources
LSE
TERN
Tern
Delayed Upgrade Clock
    ADVFN Logo
    InvestorsHub

    United Kingdom
    Company
    Business
    Popular
    Get The App
    App Store
    Google Play

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved